Details of the Drug

General Information of Drug (ID: DMYURI6)

Drug Name
Raltegravir
Synonyms
RGV; MK 0518; Isentress(TM); K-0518; MK-0518; Raltegravir (INN); N-(2-(4-(4-fluorobenzylcarbamoyl); N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide; RAL
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 444.4
Logarithm of the Partition Coefficient (xlogp) 1.1
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
Absorption
The drug is absorbed from the gastrointestinal tract []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Elimination
The drug is excreted via feces and urine []
Half-life
The concentration or amount of drug in body reduced by one-half in 9 hours [3]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 25.71535 micromolar/kg/day [4]
Chemical Identifiers
Formula
C20H21FN6O5
IUPAC Name
N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide
Canonical SMILES
CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F
InChI
InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)
InChIKey
CZFFBEXEKNGXKS-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
54671008
CAS Number
518048-05-0
DrugBank ID
DB06817
TTD ID
D0I1FQ
INTEDE ID
DR1390
ACDINA ID
D00580
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Integrase (HIV IN) TT5FH9Y POL_HV1B1 Modulator [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [5]
UDP-glucuronosyltransferase 1A1 (UGT1A1)
Main DME 		DEYGVN4 UD11_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
UDP-glucuronosyltransferase 1A9 OTPCHAFX UD19_HUMAN Drug Response [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Raltegravir
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Cobicistat DM6L4H2 Moderate Decreased metabolism of Raltegravir caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [8]
Coadministration of a Drug Treating the Disease Different from Raltegravir (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Increased metabolism of Raltegravir caused by Arn-509 mediated induction of UGT. Acute myeloid leukaemia [2A60] [9]
Sodium zirconium cyclosilicate DMCSLZ4 Moderate Decreased absorption of Raltegravir due to altered gastric pH caused by Sodium zirconium cyclosilicate. Hyperkalaemia [5C76] [9]
PF-06463922 DMKM7EW Moderate Increased metabolism of Raltegravir caused by PF-06463922 mediated induction of UGT. Lung cancer [2C25] [8]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Raltegravir caused by Rucaparib mediated inhibition of UGT. Ovarian cancer [2C73] [10]
Pitolisant DM8RFNJ Moderate Accelerated clearance of Raltegravir due to the transporter induction by Pitolisant. Somnolence [MG42] [9]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Aspartame E00402 134601 Flavoring agent
Butylated hydroxytoluene E00336 31404 Antioxidant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Monoammonium glycyrrhizate E00352 62074 Emulsifying agent; Flavoring agent
Oleic acid E00421 445639 Emulsifying agent; Penetration agent; Solubilizing agent
Saccharin sodium anhydrous E00443 656582 Flavoring agent
Sodium stearyl fumarate E00545 23665634 lubricant
Sucralose E00370 71485 Flavoring agent
Ammonia E00007 222 Alkalizing agent
Calcium hydrogenphosphate E00294 24441 Diluent
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferric oxide black E00522 16211978 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Fructose E00447 2723872 Flavoring agent
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Medium-chain triglyceride E00640 Not Available Emollient; Lubricant; Surfactant
Poloxamer 407 E00646 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Sodium citrate dihydrate E00369 71474 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Haematite red E00236 14833 Colorant
Sorbitan tristearate E00516 17800859 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Ammonium hydroxide E00687 Not Available Alkalizing agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Ethyl cellulose E00699 Not Available Coating agent; Microencapsulating agent; Binding agent; Diluent; Viscosity-controlling agent
⏷ Show the Full List of 39 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Raltegravir 100 mg tablet 100 mg Chewable Tablet Oral
Raltegravir 25 mg tablet 25 mg Chewable Tablet Oral
Raltegravir 400 mg tablet 400 mg Oral Tablet Oral
Raltegravir Potassium eq 100mg base/packet powder eq 100mg base/packet Powder Oral
Raltegravir Potassium eq 25mg base Chewable tablet eq 25mg base Chewable Tablet Oral
Raltegravir Potassium eq 100mg base Chewable tablet eq 100mg base Chewable Tablet Oral
Raltegravir Potassium eq 400mg base tablet eq 400mg base Tablet Oral
Raltegravir Potassium eq 600mg base tablet eq 600mg base Tablet Oral
Raltegravir 600 mg tablet 600 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit. 2010 Dec;32(6):782-6.
6 Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen. Drug Metabol Drug Interact. 2011;26(3):139-41.
7 Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. Antimicrob Agents Chemother. 2012 Jun;56(6):2959-66. doi: 10.1128/AAC.05424-11. Epub 2012 Feb 27.
8 Cerner Multum, Inc. "Australian Product Information.".
9 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".